~ Endocrine Disorders ~
ˇ@
« Outline
1). Polycystic ovarian syndrome
2). Cushingˇ¦s syndrome
3). Congenital adrenal hyperplasia
4). Androgen-secreting ovarian and adrenal tumors
5). Androgen-producing ovarian neoplasm
6). Stromal hyperplasia and stromal hyperthecosis
7). Virilization during pregnancy
8). Virilizing adrenal neoplasms
1). Hashimotoˇ¦s thyroiditis
2). Gravesˇ¦ disease
3). Postpartum thyroid dysfunction
ˇ@
ˇ@
ˇ@
Ÿ Hirsutism
? Definition: the presence of hair in androgen-dependent sites in which hair does not
normally appear in women. Ie. ˇ§midline hairˇ¨, eg. side burns, moustache, beard,
chest or intermammary hair, and inner thigh and midline lower back hair entering
the intergluteal area.
‚ Distinguished from:
ƒ the most frequent manifestation of androgen excess in women.
Acne, chronic anovulation, virilization à hirsutism
„ Evaluation:
drug history, etc.
moon face, plethora, purple striae, dorsocervical and uspraclanicular fat pads, hair
growth pattern, etc.
a). serum androgen: total testosterone, DHEAS, and 17-hydroxyprogesteron (p 836-7)
b). If oligomenorrhea (+), check LH, FSH, prolactin, and TSH.
c). If Cushingˇ¦s syndrome is suspected, check 24-hour urine cortisol (most sensive), or
overnight dexamethasone suppression test. (p836)
ˇ@
1). Polycystic ovarian syndrome
? Clinical Definition: oligomenorrhea/amenorrhea, infertility, hirsutism, and obesity.
‚ Diagnostic Criteria:
- hyperandrogenism, chronic anovulation, exclusion of secondary causes such as
neoplasm, hyperprolactinemia, and adult-onset congenital adrenal hyperplasia.
- An elevated LH/FSH ratio is often but not always present, and cystic ovarian
changes are usually present but not essential for diagnosis.
ƒ Sonographic Findings:
generally more than 5 microcysts in each ovary
„ Long-term Risks:
hair-AN syndrome (severe insulin resistance)
ˇK Treatment: (depending on patientˇ¦s goals)
ˇP oral contraceptives:
ˇP medroxyprogesterone: 20-40 mg daily in divided dosage, or 150 im. every 6ws to 3ms
ˇP GnRH analogs: leuprolide acetate im. every 28ds
ˇP glucocorticoids:
dexamethasome 0.25 mg nightly or every other nightly, monitoring of serum cortisol.
ˇP spironolactone: 25-100 mg bid
ˇP cyproterone acetate:
cyproterone acetate 100 mg qd on D
5-15, andethinyl estradiol 30-50 m g qd on D
5-26When a desired clinical response is achieved, the dose of may be tapered gradually at 3-6
month intervals
ˇP flutamide:
ˇP temporary: shaving, etc.
ˇP permanent (electrolysis)
ˇ@
2). Cushingˇ¦s syndrome
? Causes:
Category |
Cause |
Relative Incidence |
ACTH-dependent |
Cushingˇ¦s disease Ectopic ACTH-secreting tumors Ectopic CRH-secreting tumors |
75% 60% rare |
ACTH-independent |
Adrenal cancer Adrenal adenoma Micronodular adrenal hyperplasia Iatrogenic |
15% 10% rare very common |
ACTH: adenocorticotropic hormone; CRH: cortical-releasing hormone
‚ Clinical Manifestations:
nitrogen wasting and a catabolic state (muscle weakness, osteoporosis, atrophy of the skin with striae, possible nonhealing ulcerations and ecchymoses, reduced immune resistance, and glucose intolerance)
arterial hypertention, hypokalemic alkalosis, fluid retention, pedal edema.
women: some degree of masculinization (hirsutisum, acne, oligomenorrhea
or amenorrhea, thinning of scalp hair)
men: some degree of feminization (gynecomastia and impotence)
ƒ Diagnostic Work-up: (Figure 25.2, p846)
„ Treatment:
ˇ@
3). Congenital adrenal hyperplasia (CAH)
? Genetics:
‚ Pathogenesis:
1. A relative decrease in cortisol production
2. A compensatory increase in ACTH level
3. Hyperplasia of the zona reticularis of the adrenal cortex
4. An accumulation of the precursors of the affected enzyme in the bloodstream
ƒ Clinical Presentation of Adult-onset CAH:
„ Lab. Testing:
1st. basal follicular 17-hydroxyprogesterone:
2nd. ACTH stimulation testing:
0.25 mg ACTH iv
1 hour later
17-hydroxyprogesterone > 1000 ng/dl
ˇK Treatment: dexamethasone
ˇ@
ˇ@
6). Stromal hyperplasia and stromal hyperthecosis
ˇ@
? Workup for Hyperprolactinemia: (Figure 25.4, p858)
‚ Causes of Hyperprolactinema: (Table 25.5, p856)
ˇ@
ˇ@
¤
Evaluations:total serum T4, TSH, T3
(in pregnancy, oral contraceptive, estron replacement hepatitis,and genetic abnormalities of TBG)
Antithyroglobulin antibodies, antimicrosomal antibodies, antibodies to T3 and T4, thyoid-stimulating antibodies (TSAb) or thyroid stimulating immunoglobulin (TSI), TSH-binding inhibitor immunoglobulin (TBII), thyroid growth-promoting immunoglobulin (TGI)
ˇ@
1).Hypothyroidism
ˇ@
? Causes: (Table25.9, p868)
Congenital absence of thyroid gland, external thyroid gland radiation, familial disorders and thyroxine synthesis, Hasnimotoˇ¦s thyroiditis,
131Iablation for Gravesˇ¦ disease, ingestion of antithyroid drugs, iodine deficiency, idiopathic myxedema, surgical removal of thyroid gland
Hypothalamic TRH deficiency, pituitary or hypothalamic tumors or diseases.
‚ Reproductive Effects of Hypothyroidism:
decreased fertility from ovulatory difficulties, menstrual disturbance, luteal phase defect, and
hyperprolactinemia
ƒ Hashimotoˇ¦s Thyroiditis:
cold intolerance, constipation, carotene deposition in the periorbital region, carpal tunnel
syndrome, dry skin, fatigue, hair loss, lethargy, and weight gain.
- Lab. Data: elevated TSH, elevated antithyroglobulin and antimicrosomal antibody
B. Treatment: thyroxine replacement
- monitor by TSH
ˇ@
2).Hyperthyroidism
? Causes:
‚ Reproductive Effects of Hyperthyroidism:
weight loss, menstrual irregularity, increased risk of spontaneous abortion, increased incidence of
congenital anomalies, fetal neonatal hyperthyroidism.
ƒ Gravesˇ¦ Disease:
B. Treatment:
w most commonly utilized definitive treatment in nonpregnant women
w single dose
w Any woman of childbearing age should be tested for pregnancy before use of 131I
w Propylthiouracil (PTU): the drug of choice in pregnancy
PTU 100 mg q8h over 1 month
Monitored weekly by evaluation of appetite, emotional lability, insomnia, and tremor
General rule: to lower the dosage by 50% when thyroid function returns to normal.
w Methimazole: most prescribed for nonpregnant women.
Methimazole 10 mg q8-24h
General rule: as PTU
Currently less commonly used as definite therapy
ˇ@
Filename: Endocrine Disorders
ˇ@